Not logged in Share Save
Share Save
MRI-derived wall thickness heterogeneity in hypertrophic cardiomyopathy and in carriers of sarcomeric gene mutations Aquaro, Giovanni Donato; Licordari, Roberto; Todiere, Giancarlo; Ianni, Umberto; De Gori, Carmelo; Merlo, Marco; Barison, Andrea; De Luca, Antonio; Grigoratos, Crysanthos; Raimondi, Francesca; Ait-Ali, Lamia; Festa, Pierluigi; Negri, Francesco; Bianco, Francesco; Ricci, Fabrizio; Botto, Nicoletta; Taddei, Lapo; Alberti, Mattia; Italiano, Andrea; Gargani, Luna; Faggioni, Lorenzo; Cioni, Dania; Lencioni, Riccardo; Emdin, Michele; Neri, Emanuele; Sinagra, Gianfranco; De Caterina, Raffaele; Di Bella, Gianluca Share Save
Share Save
Share Save
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B. Share Save
Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B. Share Save
Characterization of tumor response with lenvatinib (LEN) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT Mahipal, A.; Cheng, A-L.; Kudo, M.; Burgoyne, A.; Kalyan, A.; Lencioni, R.; Lopez, C.; Pracht, M.; Daniele, B.; Palmer, D.; Baron, A.; Park, J-W.; Estenson, K.; Christou, V.; Ren, M.; Vogel, A. Share Save
Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Chan, S. L.; Decaens, T.; Kudo, M.; Erinjeri, J. P.; Lencioni, R.; Bouattour, M.; Breder, V. V.; Heo, J.; Mazzaferro, V.; Park, J-W.; Alavez, A. Molina; Kee, K. M.; Xu, A.; Inaba, Y.; Dayyani, F.; Zotkiewicz, M.; McCoy, C. L.; Makowsky, M.; Sangro, B. Share Save
Hepatocellular carcinoma (vol 7, 6, 2021) Llovet, Josep M.; Kelley, Robin Kate; Villanueva, Augusto; Singal, Amit G.; Pikarsky, Eli; Roayaie, Sasan; Lencioni, Riccardo; Koike, Kazuhiko; Zucman-Rossi, Jessica; Finn, Richard S. Share Save
Looking for appropriateness in follow-up CT of oncologic patients: Results from a cross-sectional study Lencioni, Riccardo; Fanni, Salvatore Claudio; Morganti, Riccardo; Febi, Maria; Ambrosini, Ilaria; De Gori, Carmelo; Bruni, Luciana; 'Agostino, Giulia; Milazzo, Alessio; Guerri, Gianluca; Coppola, Marzia; Mazzeo, Maria Letizia; Cioni, Dania; Neri, Emanuele; D'Amore, Caterina Aida Share Save
Diagnostic Role of Native T1 Mapping Compared to Conventional Magnetic Resonance Techniques in Cardiac Disease in a Real-Life Cohort Aquaro, Giovanni Donato; Monastero, Silvia; Todiere, Giancarlo; Barison, Andrea; De Gori, Carmelo; Grigoratos, Crysanthos; Parisella, Maria Luisa; Faggioni, Lorenzo; Cioni, Dania; Lencioni, Riccardo; Neri, Emanuele Share Save
Share Save
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study Kudo, Masatoshi; Finn, Richard S.; Qin, Shukui; Han, Kwang-Hyub; Ikeda, Kenji; Cheng, Ann-Lii; Vogel, Arndt; Tovoli, Francesco; Ueshima, Kazuomi; Aikata, Hiroshi; Lopez, Carlos Lopez; Pracht, Marc; Meng, Zhiqiang; Daniele, Bruno; Park, Joong-Won; Palmer, Daniel; Tamai, Toshiyuki; Saito, Kenichi; Dutcus, Corina E.; Lencioni, Riccardo Share Save
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study Kudo, Masatoshi; Finn, Richard S. S.; Galle, Peter R. R.; Zhu, Andrew X. X.; Ducreux, Michel; Cheng, Ann-Lii; Ikeda, Masafumi; Tsuchiya, Kaoru; Aoki, Ken-ichi; Jia, Jing; Lencioni, Riccardo Share Save
Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features Aquaro, Giovanni Donato; De Gori, Carmelo; Faggioni, Lorenzo; Parisella, Maria Luisa; Aringhieri, Giacomo; Cioni, Dania; Lencioni, Riccardo; Neri, Emanuele Share Save
A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3 Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; Cohen, G.; Kudo, M. Share Save
A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients Cioni, Dania; Gabelloni, Michela; Sanguinetti, Andrea; De Rosa, Laura; Aringhieri, Giacomo; Tintori, Rachele; Candita, Gianvito; Febi, Maria; Faita, Francesco; Lencioni, Riccardo; Neri, Emanuele Share Save
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Greten, Tim F.; Abou-Alfa, Ghassan K.; Cheng, Ann-Lii; Duffy, Austin G.; El-Khoueiry, Anthony B.; Finn, Richard S.; Galle, Peter R.; Goyal, Lipika; He, Aiwu Ruth; Kaseb, Ahmed O.; Kelley, Robin Kate; Lencioni, Riccardo; Lujambio, Amaia; Mabry Hrones, Donna; Pinato, David J.; Sangro, Bruno; Troisi, Roberto, I; Wilson Woods, Andrea; Yau, Thomas; Zhu, Andrew X.; Melero, Ignacio Share Save
IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) plus bevacizumab (bev) or sorafenib (sor) Kudo, M.; Finn, R. S.; Galle, P. R.; Zhu, A.; Ducreux, M. P.; Cheng, A-L.; Verret, W.; Gaillard, V. E.; Nicholas, A.; Lencioni, R. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
Share.png){kind=icon}
Save